Current Report Filing (8-k)
March 22 2017 - 8:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2017
PIERIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Nevada
|
|
001-37471
|
|
EIN 30-0784346
|
(State of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
255 State Street, 9th Floor
Boston, MA 02109
United
States
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: 857-246-8998
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a corporate presentation of Pieris Pharmaceuticals, Inc.
The information set forth under this Item 7.01. Regulation FD Disclosure, including the exhibits attached hereto, shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
|
|
|
99.1
|
|
Corporate Presentation of Pieris Pharmaceuticals, Inc., dated March 22, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: March 22, 2017
|
|
|
|
PIERIS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Lance Thibault
|
|
|
|
|
Name:
|
|
Lance Thibault
|
|
|
|
|
Title:
|
|
Acting Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Corporate Presentation of Pieris Pharmaceuticals, Inc., dated March 22, 2017.
|
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Sep 2023 to Sep 2024